Dr. Michael S. Lee, M.D.
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- Yale University School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 511
Licensed in Washington since 2004, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Yale University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
OR license MD25478 · WA license MD00044319 (first issued 2004; active) -
Ophthalmology Physician
OR license MD25478 · WA license MD00044319 (first issued 2004; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Providence St Vincent Medical Center Portland, OR
Medical groups
- Retina Northwest PC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 511
- Services billed
- 27,473
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 9,360 | 31 |
| Imaging of retina | 1,825 | 447 |
| Injection of drug into eye | 1,596 | 316 |
| Injection, aflibercept, 1 mg | 1,272 | 111 |
| Compounded drug, not otherwise classified | 1,031 | 202 |
| Injection, ranibizumab, 0.1 mg | 925 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 594 | 325 |
| Established patient office or other outpatient visit, 30-39 minutes | 214 | 157 |
| Photography of the retina | 91 | 87 |
| New patient office or other outpatient visit, 45-59 minutes | 86 | 86 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Portland, OR | 115 |
| Latanoprost Other prescribers in Portland, OR | 109 |
| Ketorolac Tromethamine Other prescribers in Portland, OR | 91 |
| Timolol Maleate Other prescribers in Portland, OR | 85 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Portland, OR | 75 |
| Brimonidine Tartrate Other prescribers in Portland, OR | 33 |
| Dorzolamide Hcl Other prescribers in Portland, OR | 24 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Portland, OR | 23 |
| Alphagan P (brimonidine tartrate) Other prescribers in Portland, OR | 14 |
| Loteprednol Etabonate | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 8 payments worth $933 in total to this clinician.
| Genentech USA, Inc. | $641 |
|---|---|
| Regeneron Pharmaceuticals, Inc. | $268 |
| Regeneron Healthcare Solutions, Inc. | $24.17 |
| Food and Beverage | $933 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $131,730 in research payments for these studies, mostly to the institutions running them.
- BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Bayer HealthCare Pharmaceuticals Inc. - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim Pharmaceuticals, Inc. - A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704 - A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.